Early-Stage Investments Propel Jump In Life Sciences Venture Capital
This article was originally published in The Tan Sheet
In some cases, early venture capital appears to be substituting for the public market in providing finance not only to start but also sustain companies in specialty pharma and in-licensing, development-only businesses. At least 200 capital groups took part in the 156 recorded A rounds, and 50 participated in more than one.
You may also be interested in...
Since 2013, investors have rallied around biotech IPOs like never before. START-UP looks at the current window and the implications of investor enthusiasm for newly public companies.
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.
The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.